Search Results - "Corash L"

Novel processes for inactivation of leukocytes to prevent transfusion-associated graft-versus-host disease.

Authors: Corash, L. Lin, L.

Source: Bone Marrow Transplantation. Jan2004, Vol. 33 Issue 1, p1-7. 7p. 2 Diagrams, 3 Charts, 2 Graphs.

Human platelet arylsulphatases: identification and capacity to destroy SRS-A.

Authors: Metcalfe, D. D. Corash, L. M. Kaliner, M.

Source: Immunology. Aug79, Vol. 37 Issue 4, p723-729. 7p.

P‐TS‐76 | Safety and Efficacy of Amotosalen‐UVA Pathogen Reduced Platelet Components Transfused to Mature and Premature Neonates.

Authors: Corash, L. Daskalakis, M. Mcdougall, J. et al.

Source: Transfusion. Oct2023 Supplement 5, Vol. 63 Issue S5, p305A-306A. 1p.

Pathogen inactivation of plasma components.

Authors: Corash, L. Stassinopoulos, A.

Source: Vox Sanguinis. Feb2012, Vol. 102 Issue 2, p178-179. 2p.

Assessment of hemostasis in platelet transfusion clinical trials with differential follow-up.

Authors: Sherman, C. D. Corash, L. M.

Source: Vox Sanguinis. Aug2012, Vol. 103 Issue 2, p179-179. 1p.

INTERCEPT plasma: comparability with conventional fresh-frozen plasma based on coagulation function – an in vitro analysis.

Authors: Irsch, J. Pinkoski, L. Corash, L. et al.

Source: Vox Sanguinis. Jan2010, Vol. 98 Issue 1, p47-55. 9p.

107Prevention of platelet TA-GVHD by use of intercept blood system

Authors: Lin, L. Corash, L.

Source: Biology of Blood & Marrow Transplantation. Feb2003, Vol. 9 Issue 2, p97-97. 1p.

Platelets Treated with HELNIX™ Technology (HPC) Are Effective for Multiple Cycles of Transfusion Support of Thrombocytopenia: The euroSPRITE Trial.

Authors: Corash, L. Cazenave, J. Van Rhenen, D. et al.

Source: Transfusion. Sep2001 Supplement 1, Vol. 41, p38S-38S. 1/4p.

Retraction.

Authors: Shuman, M.A. Corash, L.

Source: New England Journal of Medicine. 11/21/91, Vol. 325 Issue 21, p1487. 1/2p.

Characterization of efficacy and safety of pathogen inactivated and quarantine plasma in routine use for treatment of acquired immune thrombotic thrombocytopenic purpura.

Authors: Herbrecht, R. Ojeda‐Uribe, M. Kientz, D. et al.

Source: Vox Sanguinis. Jul2018, Vol. 113 Issue 5, p459-467. 9p. 7 Charts.

P‐TS‐24 | Design of ReCePI, a Randomized, Double‐Blinded, Phase III Study to Evaluate the Efficacy and Safety of Pathogen Reduced RBCs in Complex Cardiac Surgery.

Authors: Benjamin, R. Pitman, J. Corash, L. et al.

Source: Transfusion. Oct2023 Supplement 5, Vol. 63 Issue S5, p271A-271A. 1p.

Patient outcomes and amotosalen/ UVA-treated platelet utilization in massively transfused patients.

Authors: Nussbaumer, W. Amato, M. Schennach, H. et al.

Source: Vox Sanguinis. Apr2017, Vol. 112 Issue 3, p249-256. 8p. 3 Charts, 1 Graph.

Red blood cell concentrates treated with the amustaline (S-303) pathogen reduction system and stored for 35 days retain post-transfusion viability: results of a two-centre study.

Authors: Cancelas, J. A. Gottschall, J. L. Rugg, N. et al.

Source: Vox Sanguinis. Apr2017, Vol. 112 Issue 3, p210-218. 9p. 2 Diagrams, 3 Charts, 1 Graph.

Effect of the psoralen-based photochemical pathogen inactivation on mitochondrial DNA in platelets.

Authors: Bruchmüller, I. Lösel, R. Bugert, P. et al.

Source: Platelets. Dec2005, Vol. 16 Issue 8, p441-445. 5p.

Therapeutic efficacy of pooled buffy-coat platelet components prepared and stored with a platelet additive solution.

Authors: Van Rhenen, D. J. Gulliksson, H. Cazenave, J. P. et al.

Source: Transfusion Medicine. Aug2004, Vol. 14 Issue 4, p289-295. 7p.

Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a Chikungunya virus epidemic in Ile de La Réunion.

Authors: Rasonglès P Angelini-Tibert MF Simon P et al.

Source: Transfusion. Jun2009, Vol. 49 Issue 6, p1083-1091. 9p.

Monitoring photochemical pathogen inactivation treatment using amotosalen and ultraviolet-A light: evaluation of an indicator label.

Authors: Isola, H. Brandner, D. Cazenave, J.-P. et al.

Source: Vox Sanguinis. Nov2010, Vol. 99 Issue 4, p402-402. 1p.

Diverses formes de plasma thérapeutique traité photochimiquement pour inactivation des agents pathogènes.

Authors: Payrat, J.-M. Erickson, A. Holtan, M. et al.

Source: Transfusion Clinique et Biologique. Sep2015, Vol. 22 Issue 4, p227-228. 2p.

Hemostatic Response in Congenital Coagulation Factor-Deficient Patients Transfused with Fresh Frozen Plasma (FFP) Prepared by Helinxä Pathogen Inactivation Technology — The STEP CC Trial.

Authors: de Alarcon, P. Benjamin, R. Shopnick, R. et al.

Source: Transfusion. Sep2001 Supplement 1, Vol. 41, p89S-90S. 2p. 1 Chart.

Helinx™ Treated RBC Transfusions Are Well Tolerated and Show Comparable Recovery and Survival to Control RBCs.

Authors: Rios, J.A. Hambleton, J. Viele, M. et al.

Source: Transfusion. Sep2001 Supplement 1, Vol. 41, p38S-38S. 1/4p. 1 Chart.